CN105963292A - 一种用于心肌梗死治疗的药物组合物及其应用 - Google Patents
一种用于心肌梗死治疗的药物组合物及其应用 Download PDFInfo
- Publication number
- CN105963292A CN105963292A CN201610401454.9A CN201610401454A CN105963292A CN 105963292 A CN105963292 A CN 105963292A CN 201610401454 A CN201610401454 A CN 201610401454A CN 105963292 A CN105963292 A CN 105963292A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- myocardial infarction
- sotalol
- group
- noroxylin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000010125 myocardial infarction Diseases 0.000 title claims abstract description 33
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 25
- 238000011282 treatment Methods 0.000 title claims abstract description 15
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 claims abstract description 38
- 229960002370 sotalol Drugs 0.000 claims abstract description 36
- 239000003814 drug Substances 0.000 claims abstract description 21
- FXNFHKRTJBSTCS-UHFFFAOYSA-N baicalein Chemical compound C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 claims description 56
- 239000000203 mixture Substances 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 claims 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 abstract description 16
- 108010003415 Aspartate Aminotransferases Proteins 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 14
- 229940079593 drug Drugs 0.000 abstract description 9
- 101710088194 Dehydrogenase Proteins 0.000 abstract description 5
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 abstract description 5
- 230000001603 reducing effect Effects 0.000 abstract description 5
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 abstract description 4
- 229960003321 baicalin Drugs 0.000 abstract description 4
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 abstract description 4
- 230000000857 drug effect Effects 0.000 abstract description 2
- 230000002045 lasting effect Effects 0.000 abstract description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 abstract 2
- 229960003624 creatine Drugs 0.000 abstract 1
- 239000006046 creatine Substances 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 17
- 102000004420 Creatine Kinase Human genes 0.000 description 16
- 108010042126 Creatine kinase Proteins 0.000 description 16
- 241000700159 Rattus Species 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 229920002472 Starch Polymers 0.000 description 12
- 239000008107 starch Substances 0.000 description 10
- 235000019698 starch Nutrition 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 238000003304 gavage Methods 0.000 description 7
- 239000012467 final product Substances 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 210000000115 thoracic cavity Anatomy 0.000 description 5
- 229920001353 Dextrin Polymers 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 4
- 239000003416 antiarrhythmic agent Substances 0.000 description 4
- 210000004351 coronary vessel Anatomy 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 206010061216 Infarction Diseases 0.000 description 3
- 206010000891 acute myocardial infarction Diseases 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 235000019890 Amylum Nutrition 0.000 description 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 229960005260 amiodarone Drugs 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- BFXUWDKAQDARCA-DKWTVANSSA-N (2s)-2-aminobutanedioic acid;azane Chemical compound [NH4+].OC(=O)[C@@H](N)CC([O-])=O BFXUWDKAQDARCA-DKWTVANSSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 206010003175 Arterial spasm Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 241000237970 Conus <genus> Species 0.000 description 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015856 Extrasystoles Diseases 0.000 description 1
- 241001295925 Gegenes Species 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010049447 Tachyarrhythmia Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 229940127282 angiotensin receptor antagonist Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 108700000707 bcl-2-Associated X Proteins 0.000 description 1
- 102000055102 bcl-2-Associated X Human genes 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002308 endothelin receptor antagonist Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 239000008862 fructus schizandrae, radix ginseng, radix ophiopogonis drug combination Substances 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 210000000876 intercostal muscle Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000036391 respiratory frequency Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960003579 sotalol hydrochloride Drugs 0.000 description 1
- VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 230000003845 vascular endothelial function Effects 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
黄芩苷元 | 1g |
索他洛尔 | 10g |
微晶纤维素 | 45g |
淀粉 | 30g |
15%淀粉浆 | 适量 |
硬脂酸镁 | 2.0g |
黄芩苷元 | 10g |
索他洛尔 | 1g |
可压性淀粉 | 90g |
乳糖 | 50g |
15%淀粉浆 | 适量 |
微粉硅胶 | 1.5g |
黄芩苷元 | 10g |
索他洛尔 | 2g |
交联羧甲基纤维素钠 | 12g |
微晶纤维素 | 160g |
聚乙烯吡咯烷酮 | 6g |
5%PVP 60%乙醇溶液 | 适量 |
微粉硅胶 | 5g |
黄芩苷元 | 50g |
索他洛尔 | 5g |
可压性淀粉 | 90g |
乳糖 | 50g |
15%淀粉浆 | 适量 |
微粉硅胶 | 1.5g |
黄芩苷元 | 40g |
索他洛尔 | 8g |
淀粉 | 180g |
糊精 | 50g |
蔗糖粉 | 60g |
80%乙醇 | 适量 |
黄芩苷元 | 50g |
索他洛尔 | 50g |
淀粉 | 180g |
糊精 | 50g |
蔗糖粉 | 60g |
80%乙醇 | 适量 |
组别 | n | CK(U/L) | AST(U/L) | LDH(U/L) |
对照组 | 12 | 365±38 | 54±11 | 324±35 |
模型组 | 12 | 1348±262 | 231±44 | 1454±331 |
索他洛尔低组 | 12 | 953±58* | 168±13* | 1018±121* |
索他洛尔高组 | 12 | 873±64* | 158±16* | 914±142* |
黄芩苷元低组 | 12 | 1025±95 | 202±12 | 1207±112 |
黄芩苷元高组 | 12 | 986±63* | 195±11* | 1106±95* |
复方1组 | 12 | 658±84**#▼ | 124±29**#▼ | 859±117**#▼ |
复方2组 | 12 | 549±67**#▼▼ | 86±18**##▼▼ | 734±115**##▼▼ |
复方3组 | 12 | 437±57**##▼▼ | 68±14**##▼▼ | 610±98**##▼▼ |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610401454.9A CN105963292B (zh) | 2016-06-10 | 2016-06-10 | 一种用于心肌梗死治疗的药物组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610401454.9A CN105963292B (zh) | 2016-06-10 | 2016-06-10 | 一种用于心肌梗死治疗的药物组合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105963292A true CN105963292A (zh) | 2016-09-28 |
CN105963292B CN105963292B (zh) | 2018-11-09 |
Family
ID=57010292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610401454.9A Active CN105963292B (zh) | 2016-06-10 | 2016-06-10 | 一种用于心肌梗死治疗的药物组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105963292B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060105044A1 (en) * | 2004-05-20 | 2006-05-18 | Singh Bramah N | Sustained release formulations of sotalol |
CN101257897A (zh) * | 2005-07-07 | 2008-09-03 | 西特里斯药业公司 | 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物 |
US20080221084A1 (en) * | 2006-10-30 | 2008-09-11 | Otsuka Pharmaceutical Co., Ltd. | Method for reducing infarction using vasopressin antagonist compounds, and compositions and combinations therefor |
-
2016
- 2016-06-10 CN CN201610401454.9A patent/CN105963292B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060105044A1 (en) * | 2004-05-20 | 2006-05-18 | Singh Bramah N | Sustained release formulations of sotalol |
CN101257897A (zh) * | 2005-07-07 | 2008-09-03 | 西特里斯药业公司 | 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物 |
US20080221084A1 (en) * | 2006-10-30 | 2008-09-11 | Otsuka Pharmaceutical Co., Ltd. | Method for reducing infarction using vasopressin antagonist compounds, and compositions and combinations therefor |
Also Published As
Publication number | Publication date |
---|---|
CN105963292B (zh) | 2018-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011518785A (ja) | 心血管入院または死亡の予防に用いる薬剤を調製するためのドロネダロンの使用 | |
CN102065857A (zh) | 决奈达隆或其可药用盐在制备用于调节血钾水平的药物中的用途 | |
CN104138376A (zh) | 一种提高缺氧耐受力的缓释剂 | |
CN107007614A (zh) | 环黄芪醇的医药用途 | |
JP2015512919A (ja) | 塩酸レルカニジピンおよびロサルタンカリウム配合剤およびその調製法 | |
WO2006000137A1 (fr) | Comprime oral de notoginseng contenant de la saponine et procede de preparation | |
CN105963293A (zh) | 一种用于心肌梗死治疗的药物组合物及其应用 | |
CN105963292B (zh) | 一种用于心肌梗死治疗的药物组合物及其应用 | |
CN105982887A (zh) | 牛蒡子苷元在制备治疗高粘滞血症药物中的用途 | |
CN102065856A (zh) | 决奈达隆与至少一种利尿药的组合及其治疗用途 | |
CN101564394B (zh) | 含有伊伐布雷定和曲美他嗪的药物组合物 | |
CN109758497B (zh) | 用于慢性心力衰竭的中药组合物、药物及其制备方法和应用 | |
CN107737108B (zh) | 一种治疗心肌梗死后心室重塑的口服药物组合物 | |
CN106943390B (zh) | 马钱苷元在制备预防或治疗心律失常药物中的应用 | |
CN1762362A (zh) | 一种治疗心脑血管疾病的丹参成份药物组合物及其应用 | |
CN101167767B (zh) | 乌腺金丝桃提取物及其在制备治疗心脏病的药物中的应用 | |
CN105833051B (zh) | 一种护心通络的药物组合物及含其制剂与应用 | |
CN105853452A (zh) | 含有盐酸贝凡洛尔的药物组合物及其用途 | |
CN107982517A (zh) | 治疗心肌缺血型慢性心力衰竭的西药复方组合物 | |
CN1679846A (zh) | 一种治疗心脏疾病的中药 | |
CN104688755B (zh) | 栀子苷的医药用途 | |
CN102755319B (zh) | 一种含有普拉格雷和卡维地洛的药物组合物及其用途 | |
CN106620707A (zh) | 一种预防和治疗心肌缺血的药物组合物及其制备方法和用途 | |
CN107951885B (zh) | 一种治疗毛细血管渗漏综合征的口服药物组合物 | |
CN107998117B (zh) | 一种治疗毛细血管渗漏综合征的口服药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180925 Address after: 226000 717-718 A2 building, Jiang Haizhi Huiyuan, Nantong high tech Zone, Jiangsu Applicant after: JIANGSU HUOSHI PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Address before: 266000 1 buildings in No. 713-1 Xiangjiang Road, Huangdao District, Qingdao, Shandong. Applicant before: QINGDAO KERUIYUAN BIOTECHNOLOGY CO.,LTD. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210419 Address after: 226000 Daqing intersection, Jiaotong Road, Jinsha street, Tongzhou District, Nantong City, Jiangsu Province Patentee after: Nantong jiushengtang Biotechnology Co.,Ltd. Address before: 226000 717-718 A2 building, Jiang Haizhi Huiyuan, Nantong high tech Zone, Jiangsu Patentee before: JIANGSU HUOSHI PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221008 Address after: No. 40, Daqing Road, Jinsha Town, Tongzhou City, Nantong City, Jiangsu Province 226000 Patentee after: Gu Buzheng Address before: 226000 intersection of Jiaotong Road, Jinsha Street, Tongzhou District, Nantong City, Jiangsu Province Patentee before: Nantong jiushengtang Biotechnology Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230607 Address after: 226000 717-718 A2 building, Jiang Haizhi Huiyuan, Nantong high tech Zone, Jiangsu Patentee after: JIANGSU HUOSHI PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Address before: No. 40, Daqing Road, Jinsha Town, Tongzhou City, Nantong City, Jiangsu Province 226000 Patentee before: Gu Buzheng |
|
TR01 | Transfer of patent right | ||
CP03 | Change of name, title or address |
Address after: 230000, Building 2, Fengshang Garden, No. 247 Langxi Road, Yaohai District, Hefei City, Anhui Province, 2201 Patentee after: Anhui Fengchen Network Information Technology Co.,Ltd. Country or region after: China Address before: 226000 717-718 A2 building, Jiang Haizhi Huiyuan, Nantong high tech Zone, Jiangsu Patentee before: JIANGSU HUOSHI PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Country or region before: China |